...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer.
【24h】

Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer.

机译:腺病毒介导的自杀联合细胞因子基因治疗膀胱癌。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: The present study tests the hypothesis that adenovirus-mediated transfer of murine IL-2 (ADV/RSV-mIL-2) alone or in combination with HSV-tk + GCV will improve antitumorigenic response in the murine MBT-2 model. MATERIALS AND METHODS: mIL-2 production and toxicity were determined in vitro using an ELISA and a cell proliferation assay. Tumor-bearing animals were randomly assigned into four treatment groups and directly injected with combinations of ADV/RSV-tk and ADV/RSV-mIL-2. In a separate experiment, the above-mentioned groups were followed by two subsequent treatments with ADV/RSV-mIL-2. RESULTS: Transduced MBT-2 cells were able to express mIL-2 in a time and dose dependent fashion. We could not demonstrate any improvement in antitumorigenic response with mIL-2 gene therapy alone or in combination with HSV-tk-suicide gene therapy over HSV-tk suicide gene therapy alone. CONCLUSIONS: Although ADV/RSV-mIL-2 transduced MBT-2 cells were able to produce large amounts of mIL-2 in vitro, we could not demonstrate significant tumor growth inhibition by adding mIL-2 gene therapy to suicide gene therapy. The growth inhibitory effects of sequential suicide and cytokine gene therapy were transient and not superior to single dose suicide and cytokine gene therapy.
机译:背景:本研究检验了以下假说:腺病毒介导的鼠IL-2(ADV / RSV-mIL-2)单独转移或与HSV-tk + GCV联合转移将改善鼠MBT-2模型的抗肿瘤反应。材料与方法:使用ELISA和细胞增殖试验在体外测定mIL-2的产生和毒性。将荷瘤动物随机分为四个治疗组,并直接注射ADV / RSV-tk和ADV / RSV-mIL-2的组合。在一个单独的实验中,在上述各组之后进行了两次后续的ADV / RSV-mIL-2治疗。结果:转导的MBT-2细胞能够以时间和剂量依赖性方式表达mIL-2。我们不能证明单独使用mIL-2基因疗法或与单纯HSV-tk自杀基因疗法联合使用mIL-2基因疗法或在联合使用HSV-tk自杀基因疗法方面的抗肿瘤反应没有任何改善。结论:尽管ADV / RSV-mIL-2转导的MBT-2细胞能够在体外产生大量mIL-2,但我们无法通过在自杀基因治疗中加入mIL-2基因治疗来证明其对肿瘤生长的抑制作用。顺序自杀和细胞因子基因治疗的生长抑制作用是短暂的,并不优于单剂量自杀和细胞因子基因治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号